Remimazolam Dose for Successful Insertion of a Supraglottic Airway Device with Opioids: a Dose-Determination Study Using Dixon’s Up-and-down Method

Remimazolam, an ultra-short-acting benzodiazepine, was recently approved in numerous jurisdictions as an induction drug for general anesthesia. We aimed to determine the doses of remimazolam that would allow placement of a supraglottic airway device (SGD) in 50 https://cris.nih.go.kr ; registered 1 September 2021; principal investigator: Ji Seon Jeong).